Paricalcitol , 95% , 131918-61-1
Synonym(s):
(1α, 3β, 7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol
CAS NO.：131918-61-1
Empirical Formula: C27H44O3
Molecular Weight: 416.65
MDL number:
EINECS: 658-064-6
| Pack Size | Price | Stock | Quantity |
| 5mg | RMB3686.40 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Boiling point: | 564.8±50.0 °C(Predicted) |
| Density | 1.121±0.06 g/cm3(Predicted) |
| Flash point: | 14℃ |
| storage temp. | Store at -20°C,unstable in solution, ready to use. |
| solubility | DMSO : 100 mg/mL (240.02 mM; Need ultrasonic)Ethanol : 12.5 mg/mL (30.00 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble) |
| pka | 14.34±0.40(Predicted) |
| InChIKey | BPKAHTKRCLCHEA-UBFJEZKGSA-N |
| SMILES | C[C@]12CCC/C(=C\C=C3C[C@@H](O)C[C@H](O)C3)/[C@]1([H])CC[C@]2([H])[C@H](C)/C=C/[C@H](C)C(O)(C)C |&1:1,10,13,16,20,22,26,r| |
Description and Uses
Paricalcitol was launched as Zemplar in the US for the prevention and treatment of secondary hyperthyroidism associated with chronic renal failure. Paricalcitol is a synthetic vitamin D2, namely a novel 1-alpha-hydroxy-19-noranalogue in which the ring A exocyclic methylene group, typical of all vitamin D systems, has been replaced by two hydrogen atoms. Paricalcitol is the first vitamin D analogue marketed for this indication. In patients with chronic renal failure, Paricalcitol appreciably reduced levels of parathyroid hormone (PTH) without a significant difference in the incidence rate for hypercalcemia or hyperphosphatemia when compared with placebo.
Antihyperparathyriod
Safety
| Symbol(GHS) |   GHS06,GHS08 |
| Signal word | Danger |
| Hazard statements | H301+H311-H330-H372 |
| Precautionary statements | P280-P301+P310+P330-P302+P352+P312-P304+P340+P310-P314 |
| RIDADR | UN1170 - class 3 - PG 2 - Ethanol, solution |
| HS Code | 2936299055 |
